Home Press Press Releaeses Press Releases +++ 500 million euros for the Martinsried Life Science Campus ++++++ Lindis Biotech develops immunotherapy against bladder cancer ++++++ SIRION Biotech on course for expansion +++ PDF archive 2018 11. October 2018Gilead Sciences, ChromoTek and Johnson & Johnson Innovation present at the Biotech Press Lounge 20. August 2018Pet therapeutic antibody firm adivo announces closure of seed-financing round 2. August 2018GNA Biosolutions, a Munich based Biotech Company, wins AACC’s Disruptive Technology Award in Chicago 14. June 2018Innovative start-ups present to leading life science investors at the IZB 26. May 2018New ways to invest in cancer drugs 22. March 2018Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer 15. March 2018Origenis Appoints Thomas Loeser as Chief Financial Officer 8. February 2018New Technologies from the IZB are revolutionizing medical diagnostics 2017 5. September 2017Immunic Therapeutics Adds New Investors and Completes Series A Financing Round of Total EUR 31.7 Million 6. July 2017Start-ups profit from being in close contact with the venture capital scene 3. April 2017Europe-wide event series is very popular 12. January 2017Breakthrough technology improves genetic stem cell therapies 2016 10. November 2016Evotec and Oxford create novel partnership called “LAB282” 4. October 2016Evotec and Carrick Therapeutics build strategic alliance 29. September 2016Evotec receives further important pre-clinical milestone in endometriosis alliance with Bayer 13. September 2016LEUKOCARE grants license to US vaccine company PaxVax 9. June 2016Bicoll moves into the leading European biotech cluster 15. April 2016WuXi AppTec Acquires Crelux 2015 5. October 2015Evotec awarded multi-year contract to manage National Cancer Institute Chemical Biology Consortium Screening Libraries Center 15. September 2015‘Bodyguard’ Protein Helps Protect Young RNAs 26. August 2015„Bone adhesive“ – Innovative medicine starts as BMWi-project Biopolymers shall revolutionize the treatment of bone injuries 1. July 2015Molecular diagnostics specialist GNA Biosolutions completes € 6 million (US$ 6.7m) financing round 24. June 2015CRELUX receives 800 000 euros funding within the EU HORIZON 2020 programme to identify compounds from marine sources for age-related disease therapy 2014 5. December 2014ChromoTek strengthens its position in the highly important US market 24. July 2014CRELUX and 4SC Discovery awarded research grant for new epigenetic cancer drugs 28. May 20144SC announces positive top line data from clinical Phase I trial with epigenetic cancer drug 4SC-202 in patients with haematological tumours at ASCO 24. March 2014ChromoTek and NMI TT ally to start a new chapter in cellular high content analysis 2013 10. December 2013Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim 21. October 2013Evotec enters integrated alliance with AstraZeneca in kidney disease 16. October 2013Evotec to hold R&D Day 2013 10. October 2013Evotec and Harvard University to collaborate on exploration of enteroendocrine signals affecting key metabolic pathways 30. September 2013Evotec receives clinical milestone as part of its discovery alliance with Boehringer Ingelheim 10. September 2013SuppreMol appoints industry expert Michael Tansey as Chief Development Officer 8. August 2013Evotec AG reports H1 2013 results 8. August 20134SC reports second quarter 2013 financial results 1. August 20134SC to host conference call on 8 August 2013 to present half year results 2013 25. July 20134SC’s partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in non-small-cell lung cancer (NSCLC) in Japan 21. May 2013SuppreMol Raises € 9.5 million in Extended Series D Financing Round 16. May 2013Evotec and Harvard University to collaborate on development of new class of antibacterials 14. May 20134SC significantly improves operating result in first quarter of 2013 and resolves to focus its development strategy 10. May 20134SC to host conference call on 14 May 2013 to present first quarter results of 2013 30. April 2013Dana-Farber’s Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology 18. April 2013ChromoTek wins INDUSTRY PRIZE 2013 for its pioneering Chromobody® technology for the real time analysis of cellular molecules in live cells 26. March 2013Forward step by step with Action Plan 2016 – Continued revenue growth – Significant pipeline progress 25. March 20134SC announces financial results for a successful year 2012 18. March 20134SC to host conference call and webcast on 25 March 2013 to present full year financial results for 2012 11. March 2013ibidi is a Top Winner in the 2012/13 German Economy Innovation Award Competition 6. March 20134SC AG: Dr Ulrich Dauer to step down as CEO and member of the Management Board on 31 March 2013; his successor will be CFO Enno Spillner 26. February 20134SC Discovery and LEO Pharma announce exclusive research and license agreement for inflammatory skin diseases 20. February 20134SC Discovery and BioNTech launch strategic cancer therapy research partnership 11. January 2013Evotec achieves milestone in drug discovery collaboration with Ono Pharmaceutical Co., Ltd. 9. January 2013Evotec and Yale University form Open Innovation Alliance 8. January 20134SC obtains key patent for anti-cancer compound resminostat in Europe 7. January 2013Evotec expands collaboration with MedImmune, receives milestone payment 3. January 2013Evotec acquires Cell Culture Service GmbH 2. January 2013Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy 2012 17. December 2012Evotec announces NMDA antagonist license agreement 28. November 2012Evotec enters biology collaboration with Probiodrug 23. November 2012Evotec Receives CIR (French Research Tax Credit) Accreditation 8. August 2012Evotec H1 2012: Building innovation on the back of profitable growth 28. June 20124SC to present additional safety and efficacy data for cancer drug Resminostat from its Phase II SHELTER trial in liver cancer at ESMO GI Cancer Meeting 2011 12. May 2021AMSilk receives financing of 29 million euros 13. April 2021Lindis Biotech develops immunotherapy against bladder cancer 17. March 2021CHEManager 2021 10. March 2021Münchner Merkur 2021 1. March 2021Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins 25. February 2021ChromoTek and Absolute Antibody Collaborate on Recombinant Engineered Antibodies 11. February 2021A higher omega-3 level apparently protects from dying from COVID-19 4. February 2021World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools 3. December 2020Innovation network Proteomics4Future explores new technologies for the industrialization of MS-based proteomics 23. November 2020Proteintech uand Chromo Tek, 2020 23. November 2020Handelsblatt, 2020 23. November 2020IHK Magazine, 07-2019 23. November 2020Welt am Sonntag, 2020 23. November 2020IHK Magazine, 2019 23. November 2020Die Festschrift zum 25-jährigen Jubiläum des IZB präsentiert 70 Portraits und Visionen erfolgreicher Biotech-Start-ups 20. November 2020IZB press photos 20. November 2020Commemorative publication of the IZB 10. November 2020Festschrift for the 25th anniversary of the IZB 10. November 2020CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients 21. October 2020Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools 14. October 2020Florian Hahn, MdB, visited the corona researchers in the Innovation and Start-up Center for Biotechnology (IZB) near Munich 28. September 202013th Biotech Press Lounge 25. August 2020Visit of the Minister Kerstin Schreyer to the IZB 25. August 2020Economic reception 2019 in the IZB 25. August 2020Economic reception 2018 in the IZB 25. August 2020Economic reception 2017 at the IZB 25. August 20201. Refresh Meetup with Labiotech.eu 25. August 2020Economic reception 2015 in the IZB 25. August 2020Visit of the State Secretary for Economic Affairs Franz Joseph Pschierer to the IZB 25. August 2020Innovations Congress “Biotech made in Germany” 25. August 2020Opening of the IZB Residence CAMPUS AT HOME 25. August 2020Imagebrochure of the IZB 23. August 2020Restaurant Seven and More press photos 17. August 2020At the IZB, start-ups are working on drugs against the Sars-CoV-2 virus, as part of a consortium on a vaccine and developing new corona tests 6. August 2020MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation 3. August 2020Image video of the IZB 29. July 2020IZB In Dialog 02/2019 18. June 2020Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19 15. May 2020Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients 2. May 2020Brochure Conference Location 29. April 2020Brochure of the G2B Faculty Club 23. April 2020Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 21. April 2020GALLERY Freshmaker 21. April 2020Campus hotel press photos 21. April 2020G2B Faculty Club press photos 19. April 2020GALLERY Seven-and-more 18. April 2020GALLERY SkyRoom 17. April 202013th Biotech Press Lounge 17. April 202012th Biotech Press Lounge 16. April 202011th Biotech Press Lounge 29. March 2020Brochure CAMPUS AT HOME 16. February 202013th Biotech Press Lounge at Faculty Club G2B 17. October 201912. Biotech Press Lounge at Faculty Club G2B 12. October 2019transkript 2019 2 12. September 2019transkript 2019 1 12. August 2019Prozesstechnik 2019 12. July 2019High investor density at the Pitch Day hosted by the IZB 12. July 2019Pharma 2019 2. July 201912th Biotech Press Lounge 1. July 20195th Munich Life Science Pitch Day 24. June 2019Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update 6. June 2019IZB im Dialog 01/2019 4. June 2019Origenis GmbH Announces Research Collaboration with U.S. Cancer Center 18. May 201911th Biotech Press Lounge im Faculty Club G2B 29. April 2019Givaudan übernimmt das Kosmetikgeschäft von AMSilk 17. April 2019adivo and Bayer Animal Health sign global collaboration agreement 16. April 2019Probiodrug raises EUR 8.2 million in successful private placement of new shares 12. April 2019Laborpraxis 2019 12. April 2019Labo 2019 12. April 2019Immunic Therapeutics und Vital Therapies vollziehen Transaktion zur Schaffung eines an der Nasdaq notierten Unternehmens im Bereich chronischer Entzündungs- und Autoimmunerkrankungen 21. February 20193D bioprinted organs in five years – Dr. Ali Ertürk introduced his new technology at the 10th Biotech Press Lounge at the IZB 21. February 201910th Biotech Press Lounge 12. February 2019going public-2019 12. January 2019biotechnologiede-2019-1 17. December 20189th Biotech Presse-Lounge 14. December 2018IZB im Dialog 03/2018 11. October 2018Gilead Sciences, ChromoTek and Johnson & Johnson Innovation present at the Biotech Press Lounge 25. August 2018IZB im Dialog 03/2018 25. August 2018Conference rooms of the IZB press photos 20. August 2018Pet therapeutic antibody firm adivo announces closure of seed-financing round 12. August 2018Venture Capital 2018 12. August 2018Süddeutsche Zeitung 2018 2. August 2018GNA Biosolutions, a Munich based Biotech Company, wins AACC’s Disruptive Technology Award in Chicago 23. July 2018IZB im Dialog 02/2018 23. July 20188th Biotech Presse-Lounge 12. July 2018Münchner Merkur 2018-2 12. July 2018Münchner Merkur 2018-1 3. July 201811th Biotech Press Lounge 2. July 201810th Biotech Press Lounge 1. July 20189th Biotech Press Lounge 14. June 2018Innovative start-ups present to leading life science investors at the IZB 12. June 2018CHE Manager 2018 12. June 2018biotechnologiede-2018-3 26. May 2018New ways to invest in cancer drugs 12. April 2018Hallo München 2018 12. April 2018biotechnologie-2018-2 28. March 2018IZB im Dialog 01/2018 23. March 20187th Biotech Press Lounge 22. March 2018Origenis Appoints Dr. Peter Seufer-Wasserthal as Chief Business Officer
